Mutant IL-2 Immunoconjugate Selective T Cell Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current IL-2 immunotherapy for cancer faces challenges such as toxicity due to vascular leak syndrome, tumor tolerance, and immunosuppression, and inefficiencies in targeting tumor cells, including antigen shedding or downregulation, and suboptimal contact with effector cells in tumor microenvironments.
Innovation Solution
A method involving the administration of nucleated cells with an exogenous antigen and an immunoconjugate comprising a mutant IL-2 polypeptide with specific amino acid substitutions (F42A, Y45A, and L72G) that binds to T cells or tumor cell environments, enhancing immune responses while reducing toxicity and improving targeting.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high-dose IL-2 treatment is administered to expand lymphocyte populations and increase effector functions, then antitumor effects are improved, but severe side effects including vascular leak syndrome occur
Solution Approach 1:
The patent applies local quality by creating mutant IL-2 polypeptides with specific amino acid substitutions (F42A, Y45A, L72G) that alter binding properties. These mutations make IL-2 selectively bind to activated T cells (which have high levels of IL-2 receptor beta and gamma chains) while having reduced affinity for regulatory T cells and endothelial cells. This localized differentiation in binding affinity resolves the contradiction by concentrating IL-2 effects where needed (activated effector T cells) while minimizing harmful effects elsewhere (endothelium and Tregs).
Solution Approach 2:
The patent employs parameter changes by modifying the amino acid sequence of IL-2 to create variants with altered receptor binding characteristics. The specific substitutions (Phe42Ala, Tyr45Ala, Leu72Gly) change the physical-chemical properties of IL-2, reducing its affinity for the alpha-subunit of the IL-2 receptor (CD25) while maintaining or enhancing binding to the beta-gamma heterodimer. This parameter modification allows selective expansion of effector T cells without triggering vascular leak syndrome or excessive Treg activation.
2Reliability
If IL-2 is administered to stimulate T cell responses, then lymphocyte expansion is improved, but tumor tolerance increases due to AICD
Solution Approach 1:
The mutant IL-2 polypeptides exhibit local quality in their binding preferences, showing high selectivity for activated effector T cells while having minimal effect on regulatory T cells. This selective binding pattern ensures that IL-2-driven proliferation occurs primarily in the effector T cell compartment, generating antitumor activity without the balanced proliferation of Tregs that would otherwise enforce tolerance and promote AICD of tumor-reactive clones.
3Manufacturing precision
If tumor-targeted IL-2 is used to improve contact with effector cells, then targeting efficiency is improved, but tumor cells may escape by shedding or downregulating target antigen
Solution Approach 1:
The patent applies self-service by utilizing the tumor microenvironment's own characteristics to achieve selective IL-2 delivery. The mutant IL-2 polypeptides are designed to be retained within the tumor microenvironment through binding to stromal cells and extracellular matrix components that express IL-2 receptors. This creates a localized reservoir of IL-2 that continuously exposes infiltrating effector T cells to high concentrations of cytokine, ensuring robust activation without requiring tumor cell surface antigens. The system essentially uses the tumor's own stromal compartment as the delivery vehicle, making escape through antigen loss irrelevant.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach stimulates effective endogenous T cell responses, reduces tumor growth, and minimizes side effects by selectively targeting IL-2 to effector cells and tumor environments, improving the efficacy of IL-2 immunotherapy.
Implementation Method 1
the mutant IL-2 polypeptide is a human IL-2 molecule comprising the amino acid substitutions F42A, Y45A and L72G... wherein the mutant IL-2 polypeptide shows reduced affinity to the high-affinity IL-2 receptor
Data Source
AI summary
The present application provides methods for stimulating an immune response in an individual comprising administering a composition of nucleated cells (e.g., PBMCs) comprising an intracellular exogenous antigen in conjunction with administering an immunoconjugate comprising a variant IL-2 polypeptide and a second polypeptide. The variant IL-2 polypeptide exhibits reduced affinity to the α-subunit of the IL-2 receptor. The second polypeptide targets a tumor cell or a T cell.